Sepsis Biomarkers: A Mandate Point-of-Care Tests for Every ICU in India
JASPI March 2026 / Volume 4 /Issue 1
Copyright: © Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
January – March 31, 2026
Panda PK, Perumalla S.Sepsis Biomarkers: A Mandate Point-of-Care Tests for Every ICU in India. JASPI. 2026;4(1):Page No
DOI: 10.62541/jaspi101
INTRODUCTION
Sepsis is a leading cause of mortality in ICUs in India using high resources. Despite the major advancements in critical care, case-fatality rates remain high because of delayed recognition, usage of empiric broad-spectrum antibiotics, and a high burden of multiple drug-resistant organisms (MDROs) 1, 4. The cost of antimicrobial resistance (AMR) in Indian ICUs is substantial due to longer hospital stays, expensive last resort drugs, organ support, and excess mortality, imposing a heavy financial and societal toll 4. Diagnostic uncertainty amplifies the problem when clinicians can’t rapidly distinguish bacterial causes from fungal causes of sepsis or sepsis from sterile inflammation and this leads to their default to “cover all causative agents”, accelerating AMR and adverse events. Indian experience highlights how diagnostic errors cascade into wrong antimicrobial choices and worse outcomes, strengthening the case for diagnostic stewardship as the front-end of antimicrobial stewardship (AMS) 5.
Submit a Manuscript:
Copyright © Author(s) 2026. JASPI- Journal of Antimicrobial Stewardship Practices and Infectious Diseases.
